BioLineRx (BLRX) Total Debt (2011 - 2025)

BioLineRx's Total Debt history runs 12 years deep, the most recent figure standing at $8.9 million for Q4 2025.

• On a quarterly basis, Total Debt fell 33.47% year-over-year to $8.9 million in Q4 2025; TTM through Dec 2025 was $8.9 million, a 33.47% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 33.47% from the prior year.
• Total Debt slipped to $8.9 million in Q4 2025 per BLRX's latest filing, from $10.1 million in the prior quarter.
• Across five years, Total Debt topped out at $29.4 million in Q2 2024 and bottomed at $1.0 million in Q2 2022.
• The 5-year median for Total Debt is $9.9 million (2023), against an average of $10.2 million.
• Across the five-year window, Total Debt tumbled 76.77% in 2022 and jumped 1042.45% in 2023, its largest moves.
• Year by year, Total Debt stood at $2.8 million in 2021, then surged by 268.81% to $10.2 million in 2022, then dropped by 3.88% to $9.8 million in 2023, then surged by 37.49% to $13.4 million in 2024, then plunged by 33.47% to $8.9 million in 2025.
• Per Business Quant, the three latest BLRX Total Debt figures stand at $8.9 million (Q4 2025), $10.1 million (Q3 2025), and $11.2 million (Q2 2025).